Introduction
This quiz set focuses on EU regulation of novel foods and novel food ingredients, tailored for M.Pharm students studying Regulatory Aspects of Food & Nutraceuticals. It covers key legal concepts, definitions, authorization pathways, roles of EU bodies (notably EFSA and the European Commission), the Union list, traditional foods from third countries, engineered nanomaterials, data protection, and post‑market obligations. Questions are designed to deepen understanding of the regulatory framework, dossier expectations, safety assessment principles and practical compliance issues that pharmaceutical graduates will encounter when advising on nutraceuticals and functional food ingredients in the EU market.
Q1. What is the cornerstone EU legal act currently governing novel foods and novel food ingredients?
- Regulation (EU) 2015/2283 on novel foods
- Directive 2001/83/EC on medicinal products
- Regulation (EC) No 178/2002 (General Food Law)
- Regulation (EU) 1169/2011 on food information to consumers
Correct Answer: Regulation (EU) 2015/2283 on novel foods
Q2. Under EU law, a “novel food” is primarily defined by which of the following criteria?
- Food that has a new therapeutic claim
- Food not consumed to a significant degree within the EU before 15 May 1997
- Any food produced outside the EU
- Food that contains allergens
Correct Answer: Food not consumed to a significant degree within the EU before 15 May 1997
Q3. Which EU body is responsible for the scientific risk assessment of novel food applications?
- European Medicines Agency (EMA)
- European Food Safety Authority (EFSA)
- European Commission Directorate‑General for Trade
- European Centre for Disease Prevention and Control (ECDC)
Correct Answer: European Food Safety Authority (EFSA)
Q4. Where are authorized novel foods listed so they may be legally placed on the EU market?
- The Union list of authorized novel foods
- The national registries of each Member State
- The Codex Alimentarius list
- The European Pharmacopoeia
Correct Answer: The Union list of authorized novel foods
Q5. Which category is explicitly covered by the novel foods regulation and often requires specific characterization and safety studies?
- Engineered nanomaterials used as food ingredients
- Traditional EU cheeses
- Conventional table salt
- Pasteurised milk
Correct Answer: Engineered nanomaterials used as food ingredients
Q6. How are “traditional foods from third countries” treated under the EU novel foods framework?
- They require a full novel food authorization identical to new ingredients
- They may follow a notification route if safe history of use (e.g., 25 years) is demonstrated
- They are automatically authorized if used outside the EU
- They are banned unless proven identical to an EU food
Correct Answer: They may follow a notification route if safe history of use (e.g., 25 years) is demonstrated
Q7. Who grants the final market authorization for a novel food that has received a positive scientific opinion from EFSA?
- European Commission via implementing act and inclusion in the Union list
- EFSA directly issues the market authorization
- Individual Member States grant authorization independently
- World Health Organization (WHO)
Correct Answer: European Commission via implementing act and inclusion in the Union list
Q8. Which of the following elements is typically required in a novel food application dossier?
- Comprehensive safety data including toxicology, ADME, proposed uses and intake estimates
- Only a business plan and marketing strategy
- Clinical trial data proving therapeutic efficacy
- Letters of intent from distributors
Correct Answer: Comprehensive safety data including toxicology, ADME, proposed uses and intake estimates
Q9. What role does the concept of “substantial equivalence” play in the current EU novel food assessment?
- It is a historical concept used as one approach to compare a novel food with a conventional counterpart but not the sole criterion
- It is the only legal test for novel food approval
- It automatically exempts a novel food from assessment
- It applies only to food supplements with vitamins
Correct Answer: It is a historical concept used as one approach to compare a novel food with a conventional counterpart but not the sole criterion
Q10. Which of the following is a legitimate reason the Commission might require post‑market monitoring or additional studies after authorization?
- Uncertainties in long‑term exposure or vulnerable population effects identified during assessment
- To increase the price of the authorized product
- Because the applicant requested immediate market expansion
- To delay entry into the Union list for administrative reasons only
Correct Answer: Uncertainties in long‑term exposure or vulnerable population effects identified during assessment
Q11. How is proprietary scientific data submitted in support of a novel food application protected under EU rules?
- Applicants can claim protection for proprietary data; a period of exclusivity is provided for such data
- All submitted data become public immediately with no protection
- Proprietary data are shared with competing companies automatically
- There is no mechanism to claim confidentiality for any dossier information
Correct Answer: Applicants can claim protection for proprietary data; a period of exclusivity is provided for such data
Q12. Which previous regulation did Regulation (EU) 2015/2283 replace in the EU novel food framework?
- Regulation (EC) No 258/97 on novel foods and novel food ingredients
- Directive 2002/46/EC on food supplements
- Regulation (EU) No 1169/2011 on food labelling
- Regulation (EC) No 396/2005 on pesticide residues
Correct Answer: Regulation (EC) No 258/97 on novel foods and novel food ingredients
Q13. If a novel food ingredient is substantially similar to an existing food but produced by a new production process, how does the EU regulatory framework treat it?
- It may still be considered novel and require assessment due to the new production process
- It is automatically exempted because the composition is identical
- It is regulated only as a food additive
- It is treated as a medicinal product
Correct Answer: It may still be considered novel and require assessment due to the new production process
Q14. What must an applicant demonstrate to use the “traditional food from a third country” notification instead of a full authorization?
- Evidence of safe history of use in a third country for a significant period (e.g., at least 25 years)
- That the product has been sold in the EU for 10 years already
- That it is produced by an EU company
- That it treats or prevents disease
Correct Answer: Evidence of safe history of use in a third country for a significant period (e.g., at least 25 years)
Q15. Which of the following is true about placing an unauthorized novel food on the EU market?
- It is prohibited to place on the market until authorized and included in the Union list
- It is allowed if sold only in one Member State
- It is permitted if the manufacturer claims traditional use outside the EU
- It is allowed if the novel food is labeled with safety warnings
Correct Answer: It is prohibited to place on the market until authorized and included in the Union list
Q16. Which principle underlies EFSA’s scientific assessment of a novel food application?
- A science‑based risk assessment considering hazard identification, dose‑response, exposure assessment and risk characterization
- Assessment based solely on economic benefit to EU consumers
- Approval if no Member State objects within 3 days
- Approval based on historical culinary popularity
Correct Answer: A science‑based risk assessment considering hazard identification, dose‑response, exposure assessment and risk characterization
Q17. What information about consumption is essential in a novel food dossier to support safety assessment?
- Estimated intake levels based on proposed uses and consumption data for relevant population groups
- Only the retail price and packaging size
- The number of marketing outlets planned in the EU
- Chef endorsements and culinary recipes
Correct Answer: Estimated intake levels based on proposed uses and consumption data for relevant population groups
Q18. Which safety concern would typically make EFSA request additional data before issuing a positive opinion?
- Uncertainties about genotoxicity or allergenicity from the submitted studies
- The applicant’s choice of brand name
- Minor formatting errors in the dossier PDF
- The origin country’s GDP
Correct Answer: Uncertainties about genotoxicity or allergenicity from the submitted studies
Q19. After inclusion in the Union list, which elements are typically specified for an authorized novel food?
- Specific conditions of use, maximum levels if any, and target population restrictions
- The color of the product packaging allowed
- The exclusive national distributors for each Member State
- Marketing slogans to be used
Correct Answer: Specific conditions of use, maximum levels if any, and target population restrictions
Q20. For an M.Pharm graduate advising a nutraceutical company on EU novel foods, which regulatory strategy is usually most appropriate?
- Prepare a complete, science‑based dossier addressing hazard, exposure, toxicology and proposed uses and engage early with regulatory consultants or authorities
- Launch the product and apply for authorization afterwards
- Rely solely on traditional use claims without documentation
- Register the product as a medicinal product to avoid food regulations
Correct Answer: Prepare a complete, science‑based dossier addressing hazard, exposure, toxicology and proposed uses and engage early with regulatory consultants or authorities
